Nark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 04-07-2024
- Paid Up Capital ₹ 5.30 M
as on 04-07-2024
- Company Age 14 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 04-07-2024
- Revenue 24.12%
(FY 2022)
- Profit -55.58%
(FY 2022)
- Ebitda -42.91%
(FY 2022)
- Net Worth 16.58%
(FY 2022)
- Total Assets 4.30%
(FY 2022)
About Nark Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.30 M.
The company currently has active open charges totaling ₹1.00 M.
Ritika Kumar, Navakumar Narayanan, and Sudhakara Dodla serve as directors at the Company.
- CIN/LLPIN
U51397KL2010PTC027169
- Company No.
027169
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nark Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navakumar Narayanan  | Managing Director | 08-Dec-2010 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ritika Kumar | Director | 27-Sep-2018 | Current |
| Sudhakara Dodla | Director | 20-Jul-2018 | Current |
Financial Performance and Corporate Structure Insights of Nark Pharmaceuticals.
Nark Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.12% increase. The company also saw a substantial fall in profitability, with a 55.58% decrease in profit. The company's net worth Soared by an impressive increase of 16.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nark Pharmaceuticals?
In 2021, Nark Pharmaceuticals had a promoter holding of 92.45% and a public holding of 7.55%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 29 Dec 2018 | ₹1.00 M | Open |
How Many Employees Work at Nark Pharmaceuticals?
Unlock and access historical data on people associated with Nark Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
